Mon 18 Nov 2019 AgilVax to Present Positive Preclinical Data for Monoclonal Antibody Targeting xCT at the American Association for Cancer Research’s Tumor Immunology and Immunotherapy Conference Read More
Wed 29 May 2019 AgilVax Triggers $2 Million Phase II Fast Track SBIR Grant and Initiates GMP Manufacturing Read More
Wed 09 Jan 2019 AgilVax Elects Dr. David T. Hung, Former Founder and CEO of Medivation, to Its Board of Directors Read More
